Next generation proteasome inhibitors
16 Jul 2010
Next generation proteasome inhibitors
Views on the joint ASCO-ASH education session
Views on the joint ASCO-ASH education session
The efficacy of denosumab and zoledronic acid as treatment for prostate cancer
Circulating tumour cells in breast cancer
The influence of zoledronic acid on the treatment of endocrine-responsive early breast cancer
Frontline treatments for lymphomas
A new centre of excellence for lung cancer treatment
EHA 2010: Experts discuss treatment of elderly cancer patients
New agent eribulin prolongs survival in metastatic breast cancer
Primary end points of clinical trials - overall survival versus progression free survival.
Clinical trial Design: Comparator arms